The FDA has not approved any stem-cell therapy specifically for rheumatoid arthritis as a licensed therapeutic agent. Olfactory ensheathing cell (OEC) trials and several MSC studies are registered with the NIH but remain investigational. The EMA likewise has not cleared a marketed rheumatoid-arthritis-specific stem-cell product. Established biologic DMARDs (TNF-α inhibitors, IL-6 inhibitors, JAK inhibitors) remain the regulatory gold standard and evidence-based first-line treatment. Any marketed stem-cell therapy for RA should be scrutinised for regulatory status; unapproved claims should raise concerns.
Rheumatoid arthritis is a chronic autoimmune condition where the immune system erroneously attacks joint synovium, causing inflammation, cartilage degradation, and bone erosion. Stem-cell investigations, primarily using placental mesenchymal stem cells, explore whether these cells can modulate the underlying immune dysregulation and reduce synovial inflammation. MSCs secrete immunosuppressive cytokines and may shift macrophage polarisation from pro-inflammatory (M1) to anti-inflammatory (M2) phenotypes. With 43 registered trials and 7 currently recruiting, the therapeutic premise differs from muscular dystrophy: rather than direct tissue regeneration, MSCs aim to suppress the aberrant T-cell and B-cell responses driving the disease. Early clinical data suggest potential for joint-specific injection or systemic administration to reduce disease activity scores and inflammation markers.
Am I a candidate? → · Rheumatoid Arthritis: full overview → · Rheumatoid Arthritis cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估